Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • PR Newswire Amplify™
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • IR
  • All Products
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • IR
  • All Products
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • Sign Up
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media Enquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR

New Medical Cannabis Research Chair - Studying cannabis plants to find new therapeutic avenues

Français

News provided by

Université de Sherbrooke

May 23, 2018, 12:20 ET

Share this article

Share toX

Share this article

Share toX

SHERBROOKE, QC, May 23, 2018 /CNW Telbec/ - If cannabis is a known and recognizable plant, the fact remains that all of its secrets are not yet revealed. While North American society is facing an opioid crisis use, researches into the possibilities of using different cannabis compounds as an alternative have so far been few. However, several therapeutic avenues seem promising: analgesic properties, anti-inflammatory, antioxidant, antidepressant and anxiolytics effects.

CannaSher Inc. and the Université de Sherbrooke today announced the creation of the CannaSher Chair on Medical Cannabis. From left to right : Mr. Steven Blanchard, President of CannaSher, Pr Jean-Pierre Perreault, Université de Sherbrooke’s Vice-President, Research and Graduate Studies, Pr Kamal Bouarab, holder of the CannaSher Chair on Medical Cannabis, Pr Claude Spino, Vice-Dean of Research at the Faculty of Sciences. (CNW Group/Université de Sherbrooke)
CannaSher Inc. and the Université de Sherbrooke today announced the creation of the CannaSher Chair on Medical Cannabis. From left to right : Mr. Steven Blanchard, President of CannaSher, Pr Jean-Pierre Perreault, Université de Sherbrooke’s Vice-President, Research and Graduate Studies, Pr Kamal Bouarab, holder of the CannaSher Chair on Medical Cannabis, Pr Claude Spino, Vice-Dean of Research at the Faculty of Sciences. (CNW Group/Université de Sherbrooke)

To explore the full potential of cannabis plants and to identify the most promising molecules, CannaSher Inc. and the Université de Sherbrooke today announced the creation of the CannaSher Chair on Medical Cannabis.

An investment of more than one million

This research chair is made possible by the investment of $900 000 from CannaSher. It also benefits from a contribution of $703 700 from the Université de Sherbrooke. The Chair will have a budget totalling $1 603 700 to carry out its research. The creation of the Chair will be used as leverage to obtain additional research funding in this area.

Led by Pr. Kamal Bouarab of the Department of Biology, the CannaSher Chair will generate and improve cannabis shoots capable of producing various cannabinoids (molecules of therapeutic interest). In addition, Pr. Bouarab will test and optimise a new culture system developed by CannaSher to grow cannabis plants. The work of the Chair will also make it possible to train students in undergraduate and graduate studies as part of the research program.

"Today's announcement of the Chair is an important milestone for CannaSher and is in line with our commitment to innovation and research in the field of medical cannabis," said Steven Blanchard, President of CannaSher. "We are very proud to work in partnership with the Université de Sherbrooke and with Pr. Bouarab. We are convinced that Pr. Bouarab's research will contribute to increase our scientific understanding of cannabis and its medical use and will ultimately improve the health of Canadians and patients around the world."

Professor Jean-Pierre Perreault, Université de Sherbrooke's Vice-President, Research and Graduate Studies, welcomes this investment in research: "It is in the DNA of Université de Sherbrooke to develop innovative approaches both in partnerships and financing. CannaSher is a young company for whom research quality is fundamentally important. The business alliance we are beginning with these entrepreneurs is part of our vision for the university's research."

Why study cannabis?

"Cannabinoids are substances produced by animals and humans as potent remedies against various symptoms including pain, depression, loss of appetite, anxiety, or inflammation, commented Professor Kamal Bouarab, holder of the CannaSher Chair on Medical Cannabis. Cannabis plants produce a hundred cannabinoids, some of which have effects similar to the ones we produce ourselves. In collaboration with CannaSher, our research will help to promote certain molecules in plants, so that their effects can be studied in a therapeutic context."

Indeed, the legalization of the therapeutic use of cannabinoids in Canada is still recent. Although THC, used in particular for recreational use and CBD, a molecule which has been the subject of some research, the various components of cannabis have largely been unexplored to date. A situation that the CannaSher Chair wishes to change. 

About CannaSher

CannaSher Inc. is a privately-owned Quebec corporation headquartered in Sherbrooke. The corporation is in the process of obtaining its licences as a medical marijuana producer and distributor under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). CannaSher will manufacture cannabis-based products and cannabis oils for medical applications. CannaSher's production of cannabis for medical purposes is expected to commence by the end of 2018.

Research at the Université de Sherbrooke

The Université de Sherbrooke is at the heart of one of Quebec's three major research centres. Recognized for its sense of innovation, the UdeS is a leading partner of superior and regional governments to promote social, cultural and economic development. It also stands out for the strong growth of its research activities over the past few years, its success in technology transfer as well as its entrepreneurship and open innovation initiatives in collaboration with industrial and social partners.

Note to news editors: Photos are available upon request. 

SOURCE Université de Sherbrooke

Johanne Leroux, Communications Officer, Faculty of Sciences, Université de Sherbrooke, 819 821-8000, extension 67085, [email protected]; Yvan Vanier, Vice-president Development & Marketing, CannaSher Inc., 1 514.916.0444, [email protected]

Related Links

http://www.usherbrooke.ca/

Modal title

Organization Profile

Université de Sherbrooke

    Also from this source

  • UdeS research to benefit from high-level expertise - Valérie Laflamme named Vice-Rector of Research and International Relations at the Université de Sherbrooke

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Platform Login
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Platform
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.